Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Destinasi Tirta Nusantara Tbk (PDES) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance

Destinasi Tirta Nusantara TbkTrade
Tempo Scan Pacific Tbk.Trade

Price performance (Past 24H)

Key statistics

Destinasi Tirta Nusantara Tbk vs Tempo Scan Pacific Tbk. — how do they compare? Destinasi Tirta Nusantara Tbk trades at Rp384 (market cap 275.99B, 77.3K 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,730 (market cap 12.36T, 1.41M 24h volume). The key difference: Tempo Scan Pacific Tbk. is far larger — about 44.8× Destinasi Tirta Nusantara Tbk's market cap, and Tempo Scan Pacific Tbk. is more actively traded (1.41M versus 77.3K). Which is the better fit depends on your goals.

PDESTSPC
Market Cap
275.99B12.36T
Volume
77.3K1.41M
Lot
77314.08K
Turnover
29.21M3.83B
Average Price
377.922,722.04
Value
29.21M3.83B
Indicative Equilibrium Price
3842,730
Indicative Equilibrium Volume
2002.51K

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

PDES
View details
TSPC
View details

About Destinasi Tirta Nusantara Tbk

PT Destinasi Tirta Nusantara Tbk (the company) was established on 30 Oct 1999 based on Notaries Deed No. 36 and the deed of establishment was approved by the the Ministry of Justice dated Feb 23, 2000. The Company’s articles of association has been amended several times, most recently by notarial deed No. 187 and No.136 of Wijanto Suwongso, S.H., dated Jun 28, 2007 and 24 Oct 07, concerning among others, increase authorized, Paid up Capital, par value and public offering.

Read more on PDES

About Tempo Scan Pacific Tbk.

PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.

Read more on TSPC